Dr. Philip McCarthy discusses the MM-020, or the FIRST study, looking at the superiority of an RD induction versus MPT and if RD only should be given for a fixed number of cycles or until progression.

Dr. Philippe Moreau discusses the role of serum free light chain assay for the detection and monitoring of multiple myeloma.

Dr. Philippe Moreau discusses diagnosing multiple myeloma in a patient that is not secreting proteins but presents with CRAB symptoms.

Dr. Paul Richardson discusses current trials that support the use of three-agent regimens as consolidation therapy to improve progression-free survival.

Dr. Philippe Moreau explains the role of the Bence-Jones test and what it measures when diagnosing multiple myeloma in a patient.

Dr. Robert Orlowski discusses tips used at MD Anderson to ensure patients report all side effects related to their treatment.

Dr. Robert Orlowski explains the CyBorD regimen and its safety and efficacy as an induction therapy.

Dr. Adam Cohen discusses treatment goals for maintenance therapy in myeloma.

Dr. Raphael Fonseca explains the criteria for a very good partial response in multiple myeloma.

Dr. Raphael Fonseca explains 'stable disease' in the multiple myeloma setting.